NEWS COMMENTARY

Heterocyclic lipids conjugated to mRNA vaccines increase anti-tumor efficacy

Published:
October 01, 2019
Coverage:
Emerging Ecosystems in Agrifood and Health More...
Activities:
Research
by Joshua Haslun
Very important

A team at the Koch Institute for Integrative Cancer Research and the Massachusetts Institute of Technology identified lipid nanoparticles that not only aid in the delivery of scalable RNA vaccines but also act as adjuvants, boosting a vaccine's effectiveness. This is a solution to an ongoing issue for RNA vaccines, developing sufficient immunogenicity. While the initial research targets anti-tumor applications, there are numerous adjacent applications for the lipid nanoparticles across human and animal health. RNA vaccines are available for the livestock industry, but as herd health and management drives industry innovation and diseases impair production, clients should consider lipid nanoparticles for improved mRNA vaccine efficacy.

For the original news article, click here .


Further Reading

First-ever FDA approval for an RNA interference drug granted to Alnylam's costly Onpattro treatment for hATTR-caused nerve damage

Case Study | November 02, 2018

Alnylam Pharmaceuticals is a relatively small Boston‑based company, founded in 2002, that has been burning through cash – last year, it spent more than $0.5 billion and made only about $100 million. Its lead product, revusiran, failed in clinical trials in 2016, but Alnylam has nonetheless kept up ... Not part of subscription

Otsuka partners with Click Therapeutics to develop a new digital therapeutic to treat depression

News Commentary | January 08, 2019

Click Therapeutics, a digital therapeutic developer, will partner with Otsuka to develop a digital therapeutic to treat major depressive disorder (MDD). This comes just months after Otsuka announced its collaboration with Proteus Digital Health on its ingestible sensor pill platform. Otsuka isn't ... Not part of subscription

Microneedles build value proposition in new birth control application

News Commentary | January 22, 2019

Georgia Tech has created a form of long‑acting birth control that uses microneedles as the delivery mechanism. Microneedles are a transdermal delivery system where a treatment compound is extruded into tiny needles on a patch and pressed into the skin. When the patch is removed, the needles remain ... Not part of subscription